FindTrial
Sign In

The pharmacogenomics of valproic acid

Pharmacogenomic study of valproic acid pharmacokinetics, pharmacodynamics and adverse drug reactions in epilepsy patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016477
Enrollment
Unknown
Registered
2018-06-03
Start date
2018-06-25
Completion date
Unknown
Last updated
2018-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

epilepsy

Interventions

Case series:None

Sponsors

Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Chinese Han population; 2. Patients diagnosed with epilepsy by clinicians and electroencephalograms and treated with valproic acid; 3. Aged 0-70 years with effective contact information; 4. Voluntary participation and signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating woman; 2. Other problems affecting patient compliance; 3. Severe organic disease or any progressive disease; 4. Liver and kidney insufficiency or suffering infectious diseases or other serious complications such as preexisting cardiovascular disease, hemorrhage, etc.; 5. Patients who cannot obtain complete and important clinical data; 6. Patients who do not cooperate with this study and have an extreme personality and cannot follow up.

Design outcomes

Primary

MeasureTime frame
VPA plasma concentrations;Number of seizures;adverse reactions;—

Countries

China

Contacts

Public ContactZanling Zhang

Xiangya Hospital, Central South University

zanlingzhang2015@qq.com+86 13637313928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026